Somatic tumor mutations of serine/threonine kinase 11 (STK11), KRAS, catenin beta 1 (CTNNB1), Kelch-like ECH-associated protein 1 (KEAP1), cyclin-dependent kinase inhibitor 2B (CDKN2B), and MET were associated with an increased risk of CAT in patients with solid tumors in a large cohort including many cancer types [47]. Here, CDKN2B is linked to cancer.